The Medical Services Advisory Committee has responded to the health minister's assessment of its decision-making as "clunky" and causing deaths due to delays in funded access by deferring an outcome on the therapy that was the source of the critique.
MSAC doubles-down and defers outcome despite minister's criticism of delays and deaths
February 23, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Government turns again to cheaper medicines as Guild eyes co-payment freeze
November 19, 2026 - - Latest News -
New Zealand risks losing $763 million clinical trials sector as other countries step up
November 19, 2026 - -
A tale of two government programs - one held flat and the other still running hot
November 19, 2026 - - Latest News -
Moderna's mRNA flu vaccines and a GLP-1 review headline March PBAC agenda
November 19, 2026 - - Latest News -
Immutep goes back to smaller batch efti after review finds glycan differences in failed trial drug
November 18, 2026 - - Australian Biotech -
Genetic Signatures walks away from Microba merger after funding shortfall
November 18, 2026 - - Australian Biotech -
Hungary's Gedeon Richter offers $604 million for Mayne Pharma
November 18, 2026 - - Latest News

